Drug Profile
Research programme: atopic dermatitis therapeutic - NeoPharm
Latest Information Update: 14 Jul 2016
Price :
$50
*
At a glance
- Originator NeoPharm Co
- Class Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 14 Jul 2016 No recent reports on development identified for Atopic dermatitis in South Korea (unspecified route)